Close search filters
Changing filters will change the listed Success Criteria and Techniques
Category
Topic
Search results (204)
Article
Accredo multi-modal supports medication adherence
June 03, 2025
Study shows multi-modal clinical support participation drives higher medication adherence for new patients.
Article
As more gene therapies come to market, payers need expanded options to protect their plans
August 28, 2024
Newsroom
With Heavy Alcohol Use Increasing, Evernorth Expands Access To Treatment with Monument’s Virtual Services
February 15, 2022
Through the Evernorth Behavioral Health Network, customers can now use Monument’s online peer support, personalized therapy, and provider-prescribed medication to help them achieve sobriety or moderat...
Newsroom
New Express Scripts app feature gives customers easy, secure access to digital COVID vaccination record
September 20, 2021
Article
Three Ways to Help Your Members Avoid Interrupted Fertility Treatment
April 12, 2023
A well-designed fertility benefit helps members stay on treatment, reducing wasted dollars
Article
Designing plans to manage comorbid conditions
August 25, 2023
Health plans that address and manage complex chronic conditions such as cardiovascular disease, obesity, and diabetes have a competitive advantage.
Newsroom
Express Scripts by Evernorth Members Paid Less for Their Share of Prescriptions in 2023 Despite Drug Price Increases
June 19, 2024
Members with employer-sponsored insurance saw about a 1% decrease in their portion out-of-pocket costs for their prescription medicines last year, paying an average of $15.10 for a 30-day supply
Article
Underserved Communities at Greater Risk for Non-adherence to Diabetes Medication
May 12, 2022
Evernorth Geographic Social Determinants Index (EGSDI) identifies opportunities for proactive patient and community engagement for individuals diagnosed with type 2 diabetes.
Article
Copay Assistance Strategy Reduces Financial Burdens for Plans And Patients
October 07, 2021
Innovative solution provides $0 member cost for costly specialty drugs while reducing plans’ costs